Search results

Global Health Diagnostics

New TB tools need to be affordable in the private sector: The case study of Xpert MTB/RIF

Madhukar Pai - May 7, 2018
Please see this new paper, which includes updated data on what patients pay for Xpert MTB/RIF testing in the private health sector in highly privatized health markets. It is an update of a previous st...
access to diagnostics GeneXpert MTB/RIF pricing private sector health tuberculosis
[ARCHIVED] Young Professionals Chronic Disease Network

Study: Estimated generic prices for 4 patented cancer drugs

Eric Obscherning - Feb. 12, 2016
A study conducted on estimated generic prices of four patented oral cancer drugs (imatinib, erlotinib, sorafenib, lapatinib) has been published a few weeks ago in BMJ Open. Our favorite sentence: "...
cancer cancer care drug Essential Medicines pricing
[ARCHIVED] Young Professionals Chronic Disease Network

Just released: ACCISS Study in The Lancet Diabetes & Endocrinology

Eric Obscherning - Feb. 11, 2016
On February 9, Health Action InternationaI (HAI) published a report entitled 'Access to insulin: current challenges and constraints' and The Lancet Diabetes & Endocrinology published a companion revie...
acccess to insulin cost effectiveness Diabetes Essential Medicines insulin access pharmaceuticals pricing private sector Supply Chain taxation
[ARCHIVED] Young Professionals Chronic Disease Network

A WHO GCM/NCD Prompt from Our Own Dr. Kishore

Eric Obscherning - Jan. 26, 2016
Sandeep Kishore, President of the Young Professionals Chronic Disease Network and a public health physician at Yale University is asking all of you: How can we address the huge gap between produci...
cancer chronic disease Conferences & Meetings Coordination Depression Diabetes Epilepsy Essential Medicines financing global Heart Disease international health knowledge gap Lung Disease mental health Nutrition Obesity prevention pricing Tobacco Control